ライフサイエンスコーパス: oxotremorine M

1 ressive decrease in the apparent affinity of oxotremorine-M).

2 entiation of AMPK phosphorylation induced by oxotremorine-M.

3 gnificantly reduced the inhibitory effect of oxotremorine-M.

4 of N-[(3)H]methylscopolamine by the agonist oxotremorine-M.

5 nhibitor dephostatin prevented inhibition by oxotremorine-M.

6 in combination with the M2 receptor agonist oxotremorine-M.

7 The mAChR agonist oxotremorine-M (3-10 microM) dose-dependently decreased

8 efore compared the effects of bradykinin and oxotremorine-M (a muscarinic agonist) on membrane PIP(2)

9 Pretreatment with oxotremorine-M, a selective agonist of muscarinic recept

10 Furthermore, oxotremorine-M also dose-dependently increased the frequ

11 Oxotremorine-M also increased the sEPSC frequency in app

12 he magnitude of the full muscarinic agonists oxotremorine-M and cis-dioxolane.

13 st (quinuclidinyl benzilate) and an agonist (oxotremorine-M) at sites on human m(1)-, m(2)-, m(3)-, a

14 eta-Acetoxynortropane had K(i) values versus oxotremorine-M binding at m(1)-, m(2)-, and m(4)-recepto

15 and oxotremorine, had higher affinity versus oxotremorine-M binding compared to quinuclidinyl benzila

16 loxy(nor)tropanes had higher affinity versus oxotremorine-M binding compared to quinuclidinyl benzila

17 ransfected m(3)-receptors, since significant oxotremorine-M binding could not be detected.

18 At low concentrations (e.g. 0.1-1 microM oxotremorine-M), 'burst-mode' activity comprised regular

19 arter of the reduction in PIP(2) produced by oxotremorine-M, but equal reduction when PIP(2) synthesi

20 M4 subtype-preferring antagonist himbacine, oxotremorine-M caused a large increase in the sIPSC freq

21 prised to find that in M2/M4 double-KO mice, oxotremorine-M consistently increased the frequency of s

22 In wild-type mice, mAChR activation with oxotremorine-M decreased the amplitude of monosynaptic E

23 On the other hand, 1-10 microm oxotremorine-M dose-dependently increased the frequency

24 In M5 single-KO mice, oxotremorine-M failed to potentiate evoked EPSCs, and it

25 I mGluRs eliminated the inhibitory effect of oxotremorine-M in M2/M4 double-KO mice.

26 4129 did not block the stimulatory effect of oxotremorine-M in the majority of neurons from WT mice.

27 e-M or potentiated the stimulatory effect of oxotremorine-M in WT mice.

28 Strikingly, in M(5)-single KO mice, oxotremorine-M increased sEPSCs in only 26.3% neurons, a

29 The mAChR agonist oxotremorine-M increased the frequency of glutamatergic

30 Oxotremorine-M-induced activation of AP-1 was 40--53% lo

31 In M2/M4 double-KO mice, oxotremorine-M inhibited monosynaptic EPSCs in significa

32 mice, but not M(2)- or M(4)-single KO mice, oxotremorine-M inhibited sEPSCs in significantly fewer n

33 ent with the nonselective muscarinic agonist oxotremorine-M, M2, and M4 receptors underwent significa

34 , the inhibitory and potentiating effects of oxotremorine-M on EPSCs in M3 single-KO and M1/M3 double

35 Surprisingly, the effect of oxotremorine-M on sIPSCs was largely attenuated at a hig

36 t 4-DAMP abolished the stimulatory effect of oxotremorine-M on sIPSCs.

37 P55845 potentiated the stimulatory effect of oxotremorine-M on sIPSCs.

38 similarly reduced the potentiating effect of oxotremorine-M on sIPSCs.

39 Blockade of M currents by oxotremorine M or linopirdine prevented the depolarizing

40 e either attenuated the inhibitory effect of oxotremorine-M or potentiated the stimulatory effect of

41 with the largest cooperativity observed for oxotremorine M (Oxo-M) LY2119620.

42 ensitive to 100 microm Cd(2+) and 2.5 microm oxotremorine M (oxo-M), a muscarinic agonist, and fully

43 nergic agonist, and reduced 63% by 10 microM oxotremorine M (Oxo-M), a muscarinic agonist.

44 ave demonstrated that the muscarinic agonist oxotremorine-m (oxo-m) blocks the induction of presynapt

45 nts were modulated by the muscarinic agonist oxotremorine-M (oxo-M) in a manner having all of the cha

46 bation of cells with the cholinergic agonist oxotremorine-M (Oxo-M) induced an approximately 6-fold i

47 Effects of a muscarinic receptor agonist oxotremorine-M (oxo-M) on bladder afferent nerve (BAN) a

48 Stimulation of M1 receptors by 10 microM oxotremorine-M (Oxo-M) strongly reduced (to 0-10%) curre

49 behavioral responsiveness to challenge with oxotremorine-M (Oxo-M), a nonselective muscarinic acetyl

50 oth were inhibited by 1 mM Ba2+ or 10 microM oxotremorine-M (Oxo-M).

51 Oxotremorine-M (OXO-M; 10 microM) produced a reversible

52 Oxotremorine-M pretreatment protected cells from H(2)O(2

53 In M3 KO and M1/M3 double-KO mice, oxotremorine-M produced a consistent decrease in the fre

54 In M2 or M4 single-KO mice, oxotremorine-M produced a variable effect on sIPSCs; it

55 c receptors were stimulated with the agonist oxotremorine-M, several previously described currents we

56 The mAChR agonist oxotremorine-M significantly increased the frequency of

57 acetylcholine receptors (i.e. application of oxotremorine M to PTX-treated neurons) failed to elicit

58 inositol metabolism, but mutant A212E caused oxotremorine-M to become a weak partial agonist compared

59 y blocked the binding of [(3)H]NMS and [(3)H]oxotremorine-M to M2 receptors with Hill coefficients ne

60 ial Bax accumulation, also was attenuated by oxotremorine-M treatment after treatment with H(2)O(2) o

61 The inhibitory effect of oxotremorine-M was attenuated by the M2/M4 antagonist hi

62 Using the mAChR agonist Oxo M (oxotremorine M), we identified a GAR-3(mAChR)-G alpha(q)

63 gonists, acetylcholine (ACh), carbachol, and oxotremorine-M, while significantly increasing the maxim